SUMMARY Cloned cDNA sequences representing exons from the Duchenne/Becker muscular dystrophy (DMD/BMD) gene were used for deletion screening in a population of 287 males affected with DMD or BMD. The clinical phenotypes of affected boys were classified into three clinical severity groups based on the age at which ambulation was lost. Boys in group 1 had DMD, losing ambulation before their 13th birthday; those in group 2 had disease of intermediate severity, losing ambulation between the ages of 13 and 16 years; and boys in group 3 had BMD, being ambulant beyond 16 years. A fourth group consisted of patients too young to be classified. Clinical group allocation was made without previous knowledge of the DNA results.
Correlation ofclinical and deletion data in Duchenne and Becker muscular dystrophy
The DMD and BMD loci are allelic and have been localised within Xp2l. 4 5 The genomic sequences pERT876 and pXJl.17 were found to detect submicroscopic deletions, by non-hybridisation of patient DNA to these sequences, in a roportion of patients with both DMD and BMD.8 cDNAs representing exons of the DMD/BMD gene (which codes for a 14 kb mRNA104) have been used to screen for exon deletions in affected males, and have shown deletions in over half the cases of DMD and BMD.12 13 15
The size of the deletion is not simply correlated with the severity of disease. 16 17 It has been postulated that some exon deletions cause DMD while others cause the milder BMD, because deletions causing DMD shift the translational open reading frame, resulting in a severely truncated protein gene product, whereas in BMD the translational reading frame may be maintained in phase, resulting in an abnormal, but partially functional, protein product. [17] [18] [19] This would be compatible with the observation that cases of BMD often have an abnormal size of dystrophin, whereas DMD patients almost invariably have no demonstrable dystrophin.
Exon deletions, both at the 5' and in the central region of the gene, have been described which appear specifically to be associated with a milder phenotype.19 21 A 5' deletion (of exons 3 to 7) has been found in six BMD, five intermediate, and two DMD patients. 21 It is predicted that this deletion disrupts the translational reading frame. These mild phenotypes may be the result of differential splicing, an alternative in frame translation start site, or a second promoter site, which could compensate for the effects of this frameshift mutation.
Since dystrophin may be expressed in neurones,22 23 it may be important for normal neuronal development or function, and variable mental retardation may be an inherent effect of the DMD mutation. 1 24 We set out to correlate phenotypic characteristics of affected males with the position and extent of exon deletions detected using cDNA probes. Group 4 comprised boys still ambulant but below the age of 10 years at the time of the study. There were 32 boys in this group (25*8% of the total). Where assessment of severity could be made, 11 were thought to be in group 1, one in group 2, and three in group 3. This group was, however, analysed separately.
Four clinical parameters were assessed wherever possible.
(1) The age at which the child first walked (based on history from the parents). (2) The age at which two or three words were first used together to form sentences (based on history from the parents). (3) The height centile taken in the clinic before ambulation was lost. (4) The level of intelligence. When onset of walking was delayed to 18 months of age or beyond, this was categorised as abnormally delayed. Speech delay was defined as the inability to make simple sentences after the age of two years. 26 Clinical details of probands are shown in tables 1 and 2.
This study includes only those affected males who were found to have deletions of one or more exons.
Clinical data were categorised into severity groups without knowledge of the patient deletion data. Similarly, deletions were characterised without knowledge of the clinical details.
DNA analysis
Genomic DNA was made as previously described27 or, more recently, using a 340A Nucleic Acid Extractor (Applied Biosystems Ltd). DNA restriction endonuclease digestion, agarose gel electrophoresis, and Southern blotting were carried out using standard procedures. 13 30 For simplicity, the exon containing fragments were numbered 1 to 64 from the 5' end of the gene (table 3) .
Genomic deletions32 were further mapped by hybridisation against cDNA probes mapping to the deleted loci. Further deletions were detected by routine screening with cDNA probes 44.1, 47.4 or CF23a, and XJcdnal. Remaining undeleted patients were screened with 30.2, 30.1, 63.1/9, 63.1/10, and 63.1/11-14 cDNAs. Deletions detected were delineated in full with the requisite cDNAs.33
Results
A total of 163 of the 287 patients initially screened was found to have molecular deletions in the dystrophin gene, and in 142 of these the deletion was delineated with cDNA probes.33 In 124 of these patients there was sufficient clinical information to allow clinical severity group allocation. In those families where there were multiple DMD/BMD cases, the disease severity and the deletion were concordant in the different affected males. Only one affected boy per kindred was included in this survey. As far as we are aware, the deletions in this study therefore represent 124 independent mutations.
Deletions were usually defined by the presence or absence of hybridisation signals (fig 1) . The solid lines in figs 2 and 3 represent the extents of the deletions. In some cases it was not possible to define the boundary of the deletion clearly (owing to the neighbouring exon fragment giving an equivocal or obscured signal). This is denoted by a question mark in the diagram. In other cases, a junction fragment was indicated by the appearance of an aberrant sized band; this is shown by a 'J' in the diagrams (figs 2 and 3). Most deletions were simple linear deletions, but one (46116 in group 4) appeared to be a complex mutation, because of the presence of two abnormally sized bands.33 Fig .2 shows the sites and extents of the deletions found in groups 1 to 4, indicating those associated with short stature and mental retardation. Fig 3 shows the total range of deletions.
It can be seen that 74 different deletions were identified; 55 were found in only one affected boy, whereas 19 deletions were found in more than one unrelated subject. In nine of the group 4 cases sharing common deletions, where severity could be judged, there was concordance between the assessed severity of group 4 cases and those in groups 1 to 3 found to have the same deletions (see table 4 ).
There was no obvious difference between the distribution and size of deletions in boys with mental retardation and those of normal intelligence (fig 2,  table 4 ). Cases with mental retardation were not found to have deletions confined to any one region of the gene, and large deletions occurred both in boys with normal and in those with low intelligence. There was similarly no obvious difference between the distribution and size of deletions found in cases with short stature and those with normal stature.
Discussion
Within the DMD/BMD spectrum, DMD has been defined by the loss of ambulation by the age of 13 years, whereas ambulation retained beyond the age of 16 years was diagnostic of BMD.3 It can be seen from our clinical data that there is no clear dividing line between DMD and BMD, and that 10% of patients have disease of intermediate severity, where ambulation is lost between 13 and 16 years of age. This concurs with observations from other groups.34 35 Analysis of the deletions (table 4, Similarly, deletion of exon bands 9-31 gave a DMD phenotype (fig 3) , while deletion of exon bands 9-32 gave a BMD phenotype. This would suggest that exon band 32 contains a frameshift exon (or exons) to bring the BMD case back in frame. This is substantiated by the demonstration that deletion of exon band 32 alone produced a DMD phenotype in three cases.
bearing the deletion indicated.
Deletion of exon bands 33 with 34 gave rise to BMD, and inclusion of the next exon band (35) 8, 33, [33] [34] [35] [36] , and 39, suggesting that this degree of variation in phenotype can result from non-allelic variation, related either to genetic background or to environmental factors. In dystrophic dogs with no demonstrable dystrophin, the severity of their disease varies between litters even when they are presumed (by descent from the same affected male) to carry the same mutation.38
As previously suggested,1 3941 we found that the degree of mental retardation in muscular dystrophy was related to the severity of the disorder. It occurred in 34% of DMD patients, in 40% of those in group 2, and in 9% of boys with BMD. Severe retardation was not found in boys in groups 2 and 3, but occurred in 18% of those in group 1 (table 1) . Delayed speech occurred in 74% of boys in group 1, and 100% of boys in group 2, but also in 67% of boys in group 3 (table 1). It is doubtful whether this data on delayed speech, depending on a retrospective history from the parents, is of any discriminative value.
The distribution of deletions in boys with mental retardation was similar to that seen in all patients and showed no unique abnormalities. Three deletion types are represented by more than one patient with mental retardation (table 4; these are deletions 32, 33, and 34), but patients without mental retardation are also found to have these deletions.
Despite the suggestion that short stature with growth hormone insufficiency may be associated with amelioration of the progression of DMD,42 it appears from our survey that short stature is found more commonly in boys with severe DMD; 19% of boys in group 1 and 17% of those in group 2, but none of the boys in group 3, were at or below the 3rd centile for height. Short stature may therefore be one of the manifestations of the disease itself. 43 Affected boys with short stature were found to have deletions throughout the deletion spectrum, and boys with and without short stature share deletions 8, 28- It is hoped that studies correlating the molecular abnormalities of dystrophin with the deletion data in these patients will lead to further understanding of the pathogenetic mechanisms involved in Duchenne and Becker muscular dystrophy.
